Mitochondrial disturbances in HIV pregnancies

AIDS

Volumn 29, Issue 1, 2015, Pages 5-12

  Morén, Constanza ^a   Noguera Julián, Antoni ^a   Garrabou, Glòria ^a   Rovira, Núria ^a   Catalán, Marc ^a   Bañó, Maria ^a   Guitart Mampel, Mariona ^a   Tobías, Ester ^a   Hernández, Sandra ^a   Cardellach, Francesc ^a   Miro, Òscar ^a   Fortuny, Clàudia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiretrovirals; HAART; HIV infection; HIV pregnancies; In utero exposure; Mitochondrial dysfunction and perinatal outcomes

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EMTRICITABINE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA; RNA, MITOCHONDRIAL;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL FEATURE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; FEMALE; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANCY; INFANT; LEUKOCYTE; MAJOR CLINICAL STUDY; MOTHER; MOTHER FETUS RELATIONSHIP; NEWBORN PERIOD; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; ADVERSE EFFECTS; CROSS-SECTIONAL STUDY; CYTOLOGY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; MALE; MITOCHONDRION; MONONUCLEAR CELL; NEWBORN; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DNA, MITOCHONDRIAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LEUKOCYTES, MONONUCLEAR; MALE; MITOCHONDRIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RNA;

EID: 84928089271     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000486     Document Type: Article

References (29)

1. Giacomet V, Vigano A, Erba P, Nannini P, Pisanelli S, Zanchetta N, et al. Unexpected vertical transmission of HIV infection. Eur J Pediatr 2014; 173:121-123
2. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981
3. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010:CD008440
4. Blanche S, Warszawski J. [Tolerance of antiretroviral drugs during pregnancy]. Med Sci (Paris) 2013; 29:383-388
5. Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIVinfected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS 2000; 14:1389-1399
6. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998; 105:836-848
7. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870
8. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38:449-473
9. Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011; 57: 290-296
10. Hernandez S, Moren C, Lopez M, Coll O, Cardellach F, Gratacos E, et al. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-uteroexposed newborn. AIDS 2012; 26:419-428
11. Divi RL, Einem TL, Fletcher SL, Shockley ME, Kuo MM, St Claire MC, et al. Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci 2010; 118:191-201
12. Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol 2010; 6:1493-1504
13. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-422
14. Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrial toxicity in HAART: an overview of in vitro evidence. Curr Pharm Des 2011; 17:2130-2144
15. Chaudhry N, Patidar Y, Puri V. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes unveiled by valproate. J Pediatr Neurosci 2013; 8:135-137
16. Lopez S, Coll O, Durban M, Hernandez S, Vidal R, Suy A, et al. Mitochondrial DNA depletion in oocytes of HIV-infected antiretroviral-treated infertile women. Antivir Ther 2008; 13:833-838
17. Zuena AR, Giuli C, Venerosi Pesciolini A, Tramutola A, Ajmone-Cat MA, Cinque C, et al. Transplacental exposure to AZT induces adverse neurochemical and behavioral effects in a mouse model: protection by L-acetylcarnitine. PLoS One 2013; 8:e55753
18. Ross AC, Leong T, Avery A, Castillo-Duran M, Bonilla H, Lebrecht D, et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV Med 2012; 13:98-106
19. Moren C, Noguera-Julian A, Rovira N, Corrales E, Garrabou G, Hernandez S, et al. Mitochondrial impact of human immunodeficiency virus and antiretrovirals on infected pediatric patients with or without lipodystrophy. Pediatr Infect Dis J 2011; 30:992-995
20. Prilutskii AS, Khodakovskii AV, Mailian EA. [A method of separating mononuclears on a density gradient]. Lab Delo 1990:20-23
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254
22. Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228:35-51
23. Miró O, Cardellach F, Barrientos A, Casademont J, Rotig A, Rustin P. Cytochrome c oxidase assay in minute amounts of human skeletal muscle using single wavelength spectrophotometers. J Neurosci Methods 1998; 80:107-111
24. Gerschenson M, Nguyen V, Ewings EL, Ceresa A, Shaw JA, St Claire MC, et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004; 20:91-100
25. Gemma C, Sookoian S, Alvarinas J, Garcia SI, Quintana L, Kanevsky D, et al. Mitochondrial DNA depletion in smalland large-for-gestational-age newborns. Obesity (Silver Spring) 2006; 14:2193-2199
26. Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004; 18:1013-1021
27. Aldrovandi GM, Chu C, Shearer WT, Li D, Walter J, Thompson B, et al. Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics 2009; 124:e1189-e1197
28. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Long-term mitochondrial toxicity in HIVuninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33:175-183
29. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32:370-374.